Camrelizumab for cancers in patients living with HIV: one-single center experience

OBJECTIVES: The primary objective was to evaluate the safety of the anti-PD-1 antibody camrelizumab in people living with HIV (PLWH); the secondary objective was to evaluate tumor response. METHODS: From May 8, 2018, to December 10, 2021, twenty-four patients with HIV and advanced cancer as well as...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Menghua, Zheng, Xin, Zhang, Yu, Song, Jian, Zhao, Jimao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108516/
https://www.ncbi.nlm.nih.gov/pubmed/37062823
http://dx.doi.org/10.1186/s12981-023-00518-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108516/
https://www.ncbi.nlm.nih.gov/pubmed/37062823
http://dx.doi.org/10.1186/s12981-023-00518-y

Ejemplares similares